Diag-Nose.io develops precision diagnostic and drug-discovery solutions for respiratory disease using its RhinoMAP™ platform. RhinoMAP™ combines machine learning (artificial intelligence) with advanced proteomics to enable precision-matched treatments based on patient-specific biological endotypes. The system uses the patented ABEL Microsampler™ to collect nasal liquid biopsy samples for comprehensive biomarker analysis. Insights from the platform are intended to identify disease progression, therapeutic responsiveness, and optimal treatment pathways. The company plans to use the seed funds to expand operations and R&D. Founded in 2020 and led by CEO Eldin Rostom, Diag-Nose.io is based in Seattle, WA.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2025